The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / I•••••••• P••••• S••••••••

••• Locked

Add-on acquisitionannouncedadd-onannounced Sep 1, 2022Fact
What happened
Target
I•••••••• P••••• S••••••••
Platform
F••••••• B•••••••••add-on basis: F••••••• B•••••••••, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of I•••••••• P••••• S••••••••® ("IPS"), a division of I•••••••• B••••••••• a•• p••••••• o• c•••••••••, molecular pathology, and genomic profiling solutions. | F••••••• B•••••••••, Inc. is held by B••••••• Asset on its portfolio page; published on B••••••• Asset's own news page
Control
Control
Share acquired
unknown
Industry
healthcare / pharma
Target location
unknown
Seller kind
Corporate parent
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
5 named
Buy side
Side not stated
Evidence
“••• Locked”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 18, 2026